![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF688 |
Gene summary for ZNF688 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF688 | Gene ID | 146542 |
Gene name | zinc finger protein 688 | |
Gene Alias | ZNF688 | |
Cytomap | 16p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P0C7X2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
146542 | ZNF688 | C04 | Human | Oral cavity | OSCC | 1.72e-02 | 3.60e-01 | 0.2633 |
146542 | ZNF688 | C21 | Human | Oral cavity | OSCC | 5.97e-26 | 7.12e-01 | 0.2678 |
146542 | ZNF688 | C30 | Human | Oral cavity | OSCC | 2.23e-33 | 1.42e+00 | 0.3055 |
146542 | ZNF688 | C38 | Human | Oral cavity | OSCC | 1.87e-04 | 7.78e-01 | 0.172 |
146542 | ZNF688 | C43 | Human | Oral cavity | OSCC | 4.19e-06 | 2.16e-01 | 0.1704 |
146542 | ZNF688 | C46 | Human | Oral cavity | OSCC | 1.42e-09 | 3.66e-01 | 0.1673 |
146542 | ZNF688 | C08 | Human | Oral cavity | OSCC | 3.07e-22 | 5.07e-01 | 0.1919 |
146542 | ZNF688 | SYSMH2 | Human | Oral cavity | OSCC | 1.29e-06 | 2.87e-01 | 0.2326 |
146542 | ZNF688 | SYSMH3 | Human | Oral cavity | OSCC | 3.66e-04 | 1.90e-01 | 0.2442 |
146542 | ZNF688 | SYSMH5 | Human | Oral cavity | OSCC | 4.02e-02 | 1.49e-01 | 0.0647 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF688 | SNV | Missense_Mutation | c.323N>G | p.Asn108Ser | p.N108S | P0C7X2 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF688 | SNV | Missense_Mutation | c.767G>C | p.Arg256Pro | p.R256P | P0C7X2 | protein_coding | tolerated(0.06) | benign(0.01) | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
ZNF688 | SNV | Missense_Mutation | c.277G>C | p.Glu93Gln | p.E93Q | P0C7X2 | protein_coding | tolerated(0.15) | possibly_damaging(0.544) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF688 | SNV | Missense_Mutation | c.387N>T | p.Lys129Asn | p.K129N | P0C7X2 | protein_coding | tolerated(0.46) | benign(0) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
ZNF688 | SNV | Missense_Mutation | novel | c.227N>A | p.Ser76Tyr | p.S76Y | P0C7X2 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF688 | SNV | Missense_Mutation | c.77N>C | p.Val26Ala | p.V26A | P0C7X2 | protein_coding | deleterious(0) | benign(0.298) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
ZNF688 | insertion | Frame_Shift_Ins | rs757983438 | c.717dupG | p.Arg240AlafsTer19 | p.R240Afs*19 | P0C7X2 | protein_coding | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ZNF688 | SNV | Missense_Mutation | novel | c.710N>T | p.Ser237Phe | p.S237F | P0C7X2 | protein_coding | deleterious(0) | benign(0.007) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF688 | SNV | Missense_Mutation | novel | c.364N>T | p.Gly122Trp | p.G122W | P0C7X2 | protein_coding | deleterious(0.03) | possibly_damaging(0.53) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF688 | SNV | Missense_Mutation | novel | c.545N>A | p.Arg182His | p.R182H | P0C7X2 | protein_coding | deleterious(0.02) | possibly_damaging(0.649) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |